NCT05701527

A Study of EBC-129 in Advanced Solid Tumours

Recruiting now Phase 1 Last updated 5 February 2026

What this trial tests

Phase 1 trial testing EBC-129 in Advanced Solid Tumours in 98 participants. Currently enrolling.

Timeline

28 April 2023

Primary endpoint
24 December 2026

24 December 2026

Quick facts

Lead sponsor	EDDC (Experimental Drug Development Centre), A*STAR Research Entities
Phase	Phase 1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	98
Start date	28 April 2023
Primary completion	24 December 2026
Estimated completion	24 December 2026
Sites	5 locations across Taiwan, Singapore, United States

Drugs / interventions tested

• EBC-129 — full drug profile →
• Pembrolizumab (pembrolizumab) — full drug profile →

Conditions studied

• Advanced Solid Tumours — all drugs for Advanced Solid Tumours →

Sponsor

EDDC (Experimental Drug Development Centre), A*STAR Research Entities — full company profile →

Who can join

18 and older, any sex, with Advanced Solid Tumours. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will assess the safety and tolerability of EBC-129 as a single agent and in combination with pembrolizumab in patients with advanced solid tumours

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Resistance to antibody-drug conjugates: A review.
   Li S, Zhao X, Fu K, Zhu S, et al · · 2025 · cited 32× · PMID 40177568 · DOI 10.1016/j.apsb.2024.12.036
2. Antibody drug conjugates in the clinic.
   Udofa E, Sankholkar D, Mitragotri S, Zhao Z. · · 2024 · cited 12× · PMID 39545074 · DOI 10.1002/btm2.10677
3. Antibody-drug conjugates in cancer therapy: current landscape, challenges, and future directions.
   Chen B, Zheng X, Wu J, Chen G, et al · · 2025 · cited 4× · PMID 41184856 · DOI 10.1186/s12943-025-02489-2
4. Overcoming resistance to antibody-drug conjugates: from mechanistic insights to cutting-edge strategies.
   Zhou K, Liu X, Zhu H. · · 2025 · cited 2× · PMID 41185045 · DOI 10.1186/s13045-025-01752-9
5. Immuno-cytotoxic convergence: integrating antibody‒drug conjugates and immunofusion proteins to overcome resistance in gastrointestinal cancers.
   Wu S, Cui R, Zhao K, Yang Z, et al · · 2026 · cited 1× · PMID 41947238 · DOI 10.1186/s13045-026-01795-6
6. Bispecific Antibody and Antibody-Drug Conjugate as Novel Candidates for Treating Pancreatic Ductal Adenocarcinoma.
   Seo H, Go D, Jung SY, Han S, et al · · 2025 · cited 1× · PMID 41154706 · DOI 10.3390/biom15101477
7. Emerging Therapeutic Approaches to Pancreatic Adenocarcinoma: Advances and Future Directions.
   Peng C, Oberstein PE. · · 2025 · cited 1× · PMID 40884689 · DOI 10.1007/s11864-025-01352-2
8. Prevalence of antibody drug conjugated-induced nausea and vomiting (ADCINV) in patients with cancer.
   Chow R, Zhang D, Kannout S, Ma A, et al · · 2026 · PMID 42068413 · DOI 10.1007/s00520-026-10674-2